Ginkgo Bioworks Holdings (DNA) Liabilities and Shareholders Equity (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $1.0 billion in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 20.13% year-over-year to $1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 billion (down 20.84% YoY) and the FY2025 annual result came in at $1.1 billion, down 18.71% from the prior year.
• Liabilities and Shareholders Equity slipped to $1.0 billion in Q1 2026, from $1.1 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.5 billion in Q4 2022 to a low of $1.0 billion in Q1 2026.
• A 5-year average of $1.7 billion and a median of $1.6 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity rose 22.61% — and 2024, when it tumbled 34.56%.
• Tracing DNA's Liabilities and Shareholders Equity over 5 years: stood at $2.5 billion in 2022, then sank by 34.42% to $1.7 billion in 2023, then declined by 17.29% to $1.4 billion in 2024, then decreased by 18.71% to $1.1 billion in 2025, then fell by 7.74% to $1.0 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.0 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.